The FDA has granted an orphan drug designation to LYT-200, a fully human IgG4 monoclonal antibody targeting galectin-9, for use as a potential therapeutic option for patients with pancreatic cancer.1
Galectin-9 serves as a key regulator of the immune response to cancer and may work in concert with PD-1 which alone can be targeted to improve the immune systems response to cancer. Galectin-9 is highly expressed across pancreatic cancer and cholangiocarcinoma, two types of cancer that respond poorly to chemotherapy and immunotherapy. A multicenter phase 1/2 study (NCT04666688) is evaluating the safety, and antitumor activity of LYT-200 both as a single agent, and in combination with either chemotherapy or anti–PD-1 therapy in patients with cholangiocarcinoma and pancreatic cancer.
1. PureTech receives orphan drug designation for wholly owned candidate LYT-200 for the treatment of pancreatic cancer. News release. PureTech Health PLC. November 11, 2021. Accessed November 11, 2021. https://bit.ly/3D7vkEz
2. Monoclonal antibody targeting galectin-9 in development for the potential treatment of solid tumors. PureTech Health PLC website. Accessed November 11, 2021. https://bit.ly/3He60yX
3. LYT-200 alone and in combination with chemotherapy or anti-PD-1 in patients with metastatic solid tumors. ClinicalTrials.gov. Updated April 6, 2021. Accessed November 11, 2021. https://clinicaltrials.gov/ct2/show/NCT04666688